Foundation for a Smoke-Free World   Report issue

Foundation Phase 2 Phase 3 Phase 4
Founded: New York NY United States (2017)

Organization Overview

First Clinical Trial
2019
NCT04188106
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Foundation for a Smoke-Free World

Active Ingredients

Drugs in Phase 4 Trials (2)

hydroxyzine (vistaril) (1 trial)

varenicline (chantix) (2 trials)

Drugs in Phase 3 Trials (3)

bupropion (wellbutrin) (1 trial)

emb-01 (1 trial)

zonisamide (Zonegran) (1 trial)

Drugs in Phase 2 Trials (2)

metyrapone (metopirone) (1 trial)

oxazepam (serax) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dyssomnias (Phase 4)

Parasomnias (Phase 4)

Sleep Wake Disorders (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 7